Navigation Links
Onyx Pharmaceuticals Appoints Ted W. Love, M.D., as Head of Research & Development
Date:2/1/2010

dicine (CIRM) Independent Citizens' Oversight Committee.

Dr. Kauffman joined Onyx in November 2009 as Interim Chief Medical Officer.  Most recently, Dr. Kauffman was Chief Medical Officer at Proteolix, Inc. where he was responsible for the clinical advancement of carfilzomib as well as their other pipeline candidates.  Previously, Dr. Kauffman was President and Chief Executive Officer of EPIX Pharmaceuticals, Inc. (previously Predix Pharmaceuticals, Inc.) from 2002 to 2008.  From 1997 to 2002, he held a number of senior medical and program leadership positions at Millennium Pharmaceuticals, Inc., where he played a key role in the development of the proteasome inhibitor VELCADE®.  Earlier in his career, he served as Medical Director at Biogen Corporation (now Biogen Idec).  Dr. Kauffman earned his undergraduate degree in biochemistry from Amherst College and his M.D. and Ph.D. in molecular biology and biochemistry from Johns Hopkins.  He trained in Internal Medicine and Rheumatology at Beth Israel Deaconess Hospital and the Massachusetts General Hospital.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer.  The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer.  Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types.  Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Eribis Pharmaceuticals Receives Investment for Clinical Development of Novel Cardiovascular Therapy
2. China Yongxin Pharmaceuticals Plans to Open Eighteen New Stores in 2010 to Further Expand Customer Base and Increase Market Share
3. Poniard Pharmaceuticals, Inc. to Present Additional Cancer Treatment Data Found Significant by TapeBeat.Com Investors
4. Peregrine Pharmaceuticals Appoints Dr. Marvin R. Garovoy as Head of Clinical Science
5. Amira Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
6. China Yongxin Pharmaceuticals Opened Three New Stores in 2009 and Expanded Customer Base
7. China Yongxin Pharmaceuticals Projects Higher Net Income and EPS on Reduced Revenue for Full-Year 2009
8. Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai
9. Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
10. Poniard Pharmaceuticals Announces $6.5 Million Financing
11. Titan Pharmaceuticals to Receive $3 Million Loan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 20, 2014 The report, ... Oligos, Enzymes, Cloning kits), Technology (Bioinformatics, Nanotechnology, ... Pharmaceuticals, Biomaterials, Bioremediation) - Global Forecast to ... drivers, threats, opportunities, and challenges. , Browse ... spread through 185 pages and in-depth TOC ...
(Date:11/21/2014)... November 20, 2014 BlueInGreen, LLC ... Solutions, LLC (Pinnacle), and PCI, Inc., leading suppliers ... they have been selected to provide a new ... Arkansas Paul R. Noland Wastewater Treatment. The ... HyDOZ® gas dissolution technology, Pinnacle Ozone’s ...
(Date:11/21/2014)... 2014 Deep Research Report on ... professional and in-depth research report on the Sodium ... like its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... US, Europe, Asia, China, Japan etc. regions) industry ...
(Date:11/21/2014)... Polaris Group announced today that the ... 1 trial of ADI-PEG 20 in combination with ... pleural mesothelioma (MPM) and non-squamous non-small cell lung ... ADI-PEG 20, both as monotherapy and in combination ... other indications, including breast cancer, melanomas, ovarian cancer, ...
Breaking Biology Technology:Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2
... /PRNewswire-FirstCall/ - The Board of Directors of,Neptune ... decided,not to re-price any options including the ... directors., About Neptune Technologies, Neptune ... for nutraceutical and pharmaceutical applications and is,sponsoring ...
... Trusted LASIK Surgeons launched its revolutionary Trusted LASIK Surgeons ... order to provide a resource for consumers seeking to ... directory apart is a unique screening process ensuring that ... Eye Surgery, Laser Surgeons in the United States are ...
... Shareholders to Reject Entire Management,Slate of InSite Vision, ... AUSTIN, Texas and HOUSTON, Sept. 11 PTV ... firm, is pleased to,announce that RiskMetrics Group -(Formerly ... corporate governance firm, recommended that the,stockholders of InSite ...
Cached Biology Technology:Neptune Technologies decided not to re-price options 2Trusted LASIK Surgeons Welcomes Leading LASIK Eye Surgery Expert, Inventor David Huang, M.D., Los Angeles, to Its Unique Lasik Directory Service 2Trusted LASIK Surgeons Welcomes Leading LASIK Eye Surgery Expert, Inventor David Huang, M.D., Los Angeles, to Its Unique Lasik Directory Service 3Trusted LASIK Surgeons Welcomes Leading LASIK Eye Surgery Expert, Inventor David Huang, M.D., Los Angeles, to Its Unique Lasik Directory Service 4Trusted LASIK Surgeons Welcomes Leading LASIK Eye Surgery Expert, Inventor David Huang, M.D., Los Angeles, to Its Unique Lasik Directory Service 5Trusted LASIK Surgeons Welcomes Leading LASIK Eye Surgery Expert, Inventor David Huang, M.D., Los Angeles, to Its Unique Lasik Directory Service 6Trusted LASIK Surgeons Welcomes Leading LASIK Eye Surgery Expert, Inventor David Huang, M.D., Los Angeles, to Its Unique Lasik Directory Service 7RiskMetrics (ISS), An Independent Proxy Advisory Firm, Recommends Voting the GOLD Card for Four of PTV's Nominees: Anderson, McInerney, Melrose, and O'Holla 2RiskMetrics (ISS), An Independent Proxy Advisory Firm, Recommends Voting the GOLD Card for Four of PTV's Nominees: Anderson, McInerney, Melrose, and O'Holla 3RiskMetrics (ISS), An Independent Proxy Advisory Firm, Recommends Voting the GOLD Card for Four of PTV's Nominees: Anderson, McInerney, Melrose, and O'Holla 4
(Date:11/4/2014)... Temple University School of Medicine announced today that ... initiative funded by the Bill & Melinda Gates ... Obstetrics, Gynecology and Reproductive Sciences; and Vice Chair ... School of Medicine will pursue an innovative global ... Biomarkers to Assess Fetal Neurodevelopment.", Grand Challenges Explorations ...
(Date:11/4/2014)... England , November 4, 2014 ... and vertical market growth   Fuel3D , ... has closed a funding round totaling $6.4 million (£4 million). ... million) funding secured earlier this year and paves the way ... in 2015. The funding round was led by ...
(Date:11/3/2014)... DUBLIN , Nov. 3, 2014 Research ... report "Cell Therapy - Technologies, Markets and Companies" ... evaluates cell therapy technologies and methods, which have already started ... Hematopoietic stem cell transplantation is replacing the old fashioned bone ... described. Cell therapy is bound to become a part of ...
Breaking Biology News(10 mins):Temple University School of Medicine receives Grand Challenges Explorations grant 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3
... indicates that wild salmon may account for just 10 ... vast majority of the fish come from hatcheries. The ... decline in the population this year, which will probably ... and recreational salmon fishing. The role of ...
... 15 years of biodiversity and climate change research ... announced formation of its Asia Center to forge ... use of environmental resources. One of the first ... Philadelphia, is with Nanjing University, one of the ...
... Inzana, the Tyler J. and Frances F. Young Professor ... Pathobiology in the Virginia-Maryland Regional College of Veterinary Medicine ... the United States Department of Agriculture to study the ... Disease Complex (BRDC). The $374,000 grant will allow ...
Cached Biology News:Hatchery fish outnumber wild chinook salmon in troubled fall run 2Hatchery fish outnumber wild chinook salmon in troubled fall run 3Hatchery fish outnumber wild chinook salmon in troubled fall run 4Hatchery fish outnumber wild chinook salmon in troubled fall run 5Academy establishes Asia Center to protect the environment 2Academy establishes Asia Center to protect the environment 3Academy establishes Asia Center to protect the environment 4Veterinary college researchers explore function of biofilm in bovine respiratory disease 2
... The enzyme glycerol 3-phosphate dehydrogenase ... phosphate (DHAP) and glycerol 3-phosphate, with ... increases significantly during differentiation of progenitor ... activity of this enzyme has been ...
... with an Affinity Chitin-binding Tag) utilizes the ... elements (termed inteins) to purify recombinant proteins ... 1 and 2). This system distinguishes itself ... ability to separate a recombinant protein from ...
... pET Host Strain Competent Cell Sets ... optimizing vector/host strain combinations The ... into E. coli is to ... can be prepared in the laboratory, greater ...
... EZ DNA Methylation Kit uses a simplified ... DNA methylation analysis. The kit is based ... place between cytosine and sodium bisulfite where ... DNA Methylation Kits innovative in-column desulphonation reaction ...
Biology Products: